Transthyretin Amyloidosis Cardiomyopathy

• CLINICAL_TRIALS trial_result · 2026-03-24
  Clinical Trial Update: Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Transthyretin Amyloid Cardiomyopathy

  A completed real-world study assessing high-dose tafamidis for its effect on neurologic disease progression in patients with mixed-phenotype…

• CLINICAL_TRIALS trial_result · 2025-09-18
  Clinical Trial Update: Transthyretin Amyloidosis Cardiomyopathy in Patients With HFpEF in Russia

  AstraZeneca-sponsored clinical trial evaluating transthyretin amyloidosis cardiomyopathy in patients with heart failure with preserved eject…

• CLINICAL_TRIALS research · 2025-02-14
  Clinical Trial Update: Efficacy and Safety of Intravenous YOLT-201 for Transthyretin Amyloidosis Cardiomyopathy [EARLY_Phase 1]

  This early-phase 1 trial from Zhejiang University is recruiting to assess the efficacy and safety of intravenous YOLT-201 for transthyretin …

• CLINICAL_TRIALS research · 2024-08-06
  Clinical Trial Update: A Phase I/IIa，Open-label, Single Ascending Dose and Dose-expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of YOLT-201 in Patients With Transthyretin Amyloidosis Polyneuropathy (ATTR-PN) or Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) [Phase 1, Phase 2]

  Phase 1/2a open-label study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of YOLT-201 in patients with transthy…

• CLINICAL_TRIALS trial_result · 2024-02-12
  Clinical Trial Update: Prevalence and Characteristics of Transthyretin Amyloidosis in Patients With Left Ventricular Hypertrophy of Unknown Etiology

  Completed clinical trial assessing the prevalence and characteristics of transthyretin amyloidosis in patients with left ventricular hypertr…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.